SLS BIO Co., Ltd (KOSDAQ:246250)
South Korea · Delayed Price · Currency is KRW 1,969.00
+85.00 (4.51%)
At close: Jun 9, 2025
SLS BIO Revenue
SLS BIO had revenue of 295.74M KRW in the quarter ending September 30, 2025, a decrease of -86.04%. This brings the company's revenue in the last twelve months to 5.47B, down -39.34% year-over-year. In the year 2024, SLS BIO had annual revenue of 8.37B, down -7.23%.
Revenue (ttm)
5.47B
Revenue Growth
-39.34%
P/S Ratio
4.91
Revenue / Employee
n/a
Employees
n/a
Market Cap
26.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.37B | -652.10M | -7.23% |
| Dec 31, 2023 | 9.02B | -1.73B | -16.08% |
| Dec 31, 2022 | 10.75B | 4.54B | 73.02% |
| Dec 31, 2015 | 6.21B | 393.13M | 6.75% |
| Dec 31, 2014 | 5.82B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LabGenomics | 89.36B |
| HLB bioStep | 71.47B |
| C&R Research | 63.97B |
| DreamCIS | 62.06B |
| DT&CRO CO. | 44.36B |
| WOOJUNG BIO | 37.12B |
| P&K Skin Research Center | 22.13B |
| BioInfra | 21.92B |